![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Division of Nutritional Sciences, University of Illinois, Urbana, IL 61801 and * Department of Human Nutrition, The Ohio State University, Columbus, OH 43201
3To whom correspondence should be addressed. E-mail: jwerdman{at}uiuc.edu.
Epidemiologic evidence suggests a possible role for lycopene-rich foods in the prevention of prostate cancer and cardiovascular disease. Despite active research in disease reduction, there is a paucity of information on the absorption, biodistribution and metabolism of lycopene. The aim of this study was to evaluate the biodistribution of 14C-lycopene (specific activity, 1.83 µCi/mg) and 14C-labeled products after an oral dose of 22 µCi of 14C-lycopene in male rats that had been prefed a lycopene-containing diet (0.25 g lycopene/ kg diet) for 30 d. The percentage of 14C excreted in feces and urine over the 168 h was 68%. Quantitatively, serum 14C levels were maintained between 3 and 24 h then decreased at 72 h (P < 0.05). At all time points the majority of tissue 14C was in the liver (
72%), although total hepatic 14C decreased after 24 h. In a comparison of the extrahepatic tissue at 168 h, the 14C was greatest in adipose tissue followed by spleen and then adrenal; 80% of the 14C in the liver was in the cis and all-trans configuration at all time points. At 3 h, the 14C in seminal vesicles was primarily in the all-trans plus 5-cis forms (70%), but by 168 h, 55% of 14C was present as 14C-polar products. Despite the presence of unlabeled lycopene in the prostate, the primary 14C form was in 14C-polar products (67–92%), even at 3 h. The percentage and amount of 14C-polar products in the dorsolateral prostate lobe increased from 3 to 24 h and then reached a plateau. The data suggest that lycopene may be metabolized differently among tissues in rats prefed lycopene.
KEY WORDS: • lycopene • lycopene metabolites • biodistribution • prostate cancer • rats
This article has been cited by other articles:
|
|
 |
|
  B. L. Lindshield, J. L. King, A. Wyss, R. Goralczyk, C.-H. Lu, N. A. Ford, and J. W. Erdman Jr Lycopene Biodistribution Is Altered in 15,15'-Carotenoid Monooxygenase Knockout Mice J. Nutr., December 1, 2008; 138(12): 2367 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Campbell, C. K. Stroud, M. T. Nakamura, M. A. Lila, and J. W. Erdman Jr. Serum Testosterone Is Reduced Following Short-Term Phytofluene, Lycopene, or Tomato Powder Consumption in F344 Rats J. Nutr., November 1, 2006; 136(11): 2813 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gajic, S. Zaripheh, F. Sun, and J. W. Erdman Jr. Apo-8'-Lycopenal and Apo-12'-Lycopenal Are Metabolic Products of Lycopene in Rat Liver J. Nutr., June 1, 2006; 136(6): 1552 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zaripheh, T. Y. Nara, M. T. Nakamura, and J. W. Erdman Jr. Dietary Lycopene Downregulates Carotenoid 15,15'-Monooxygenase and PPAR-{gamma} in Selected Rat Tissues J. Nutr., April 1, 2006; 136(4): 932 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zaripheh and J. W. Erdman Jr. The Biodistribution of a Single Oral Dose of [14C]-Lycopene in Rats Prefed Either a Control or Lycopene-Enriched Diet J. Nutr., September 1, 2005; 135(9): 2212 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Novotny What Can Pharmacokinetic Models Tell Us about the Disposition of Lycopene and the Potential Role of Lycopene in Cancer Prevention? J. Nutr., August 1, 2005; 135(8): 2048S - 2049S. [Full Text] [PDF]
|
|
|
|
|
|
P. R. Trumbo Are there Adverse Effects of Lycopene Exposure? J. Nutr., August 1, 2005; 135(8): 2060S - 2061S. [Full Text] [PDF]
|
|
